MCRI to build on CyGenics' stem cell scaffold
Friday, 13 August, 2004
Stem cell company CyGenics (ASX: CYN) will collaborate with the Murdoch Children's Research Institute to perform clinical trials demonstrating that stem cells expanded from umbilical cord blood using CyGenics subsidiary Cytomatrix's proprietary cell growth scaffold retain full functionality and effectiveness.
Cytomatrix will transfer the technology, which has been shown to work for the expansion of human bone marrow stem cells, cord blood stem cells and peripheral blood stem cells, to researchers working at the MCRI.
A grant of AUD$50,000 has been awarded to the company through the Federal Government's International Science Linkages Program to support the trials.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
